CAS: 6377-18-0; Chartreusin

该化合物是细菌(*Streptocepices chapreseus*) 生产的天然抗生素化合物,被归类为聚氯酸酯,并展示了具有多种环形和功能组的复杂结构,有助于其生物活动;Chartreusin因其抑制蛋白合成的能力而闻名,使其对各种菌株有效;其行动机制与RNA菌菌菌结合,从而干扰了翻译过程;该化合物由于在治疗细菌感染方面的潜在应用及其在开发新抗生素方面的作用,对医药化学产生了兴趣.此外,Chartreusin还展示了某些抗癌特性,促使研究其对肿瘤细胞的影响;然而,其临床用途受到毒性和抗药性发育等因素的限制.

结构式图片

欧盟法规

ECHA物质C&L通报

合成工艺路线路线简述

    📜在 Oxidase Chap D49L Mutant,还原型辅酶ⅰ体系中,化学反应 1.0H,反应生成,莱姆勃霉素
    参考文献:定向进化改变邻位氧螯合酶的催化反应轨迹
    标题:定向进化改变邻位氧螯合酶的催化反应轨迹
    摘要:Chap 是一种新型的邻位氧螯合物 (Voc) 金属酶,它的定向进化提供了被称为"chap 变体"的双功能酶,它催化了区域选择性的内二醇样邻醌裂解和开环分子的邻羟基苯甲酸脱羧.这项活动扩展了 Voc 催化库,使我们更接近具有广泛生物技术意义的人工 Voc 酶.
    DOI:10.1002/anie.202201321

    海关参考信息

    专利信息


    专利号:US-10029014-B2
    优先权日:2013-09-10
    标题:Synthesis of novel asymmetric bow-tie PAMAM dendrimer-based conjugates for tumor-targeting drug delivery
    发明人:OJIMA IWAO; WANG TAO; TENG YU-HAN
    权利人:UNIV NEW YORK STATE RES FOUND
    摘要:The present disclosure relates to a dendrimer-based conjugate of the formula V m -D-C-D′-(T-F) n , which is useful for tumor targeting drug delivery. The use of asymmetric dendrimers allow for specific targeting as well as synthetic reproducibility.

    专利号:US-2023399688-A1
    优先权日:2015-08-20
    标 题 :Compositions and multiplexed systems for coupled cell-free transcription-translation and protein synthesis and methods for using them
    发明人:CULLER STEPHANIE; CHEN IHSIUNG BRANDON; PHARKYA PRITI; VAN DIEN STEVE; BARTON NELSON
    权利人:GENOMATICA INC
    摘要:In alternative embodiments, provided herein are transcription/translation (TX-TL) systems and methods of using them for use as rapid prototyping platforms for the synthesis, modification and identification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites, from biosynthetic gene cluster pipelines. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the combinatorial biosynthesis of natural products (NPs), natural product analogs (NPAs) and secondary metabolites. In alternative embodiments, exemplary TX-TL systems as provided herein are used for the rapid prototyping of complex biosynthetic pathways as a way to rapidly assess combinatorial and biosynthetic designs before moving to cellular hosts. In alternative embodiments, these exemplary TX-TL systems are multiplexed for high-throughput (HT) automation and for prototyping engineered platforms for the synthesis or modification of natural products (NPs), and natural product analogs (NPAs) and secondary metabolites analogs.

    专利号:US-2008051323-A1
    优先权日:2004-08-21
    标 题 :Chloroquine drug compositions and methods for their synthesis
    发明人:KOSAK KENNETH M
    权利人:KOSAK KENNETH M
    摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. n The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

    专利号:US-2007060499-A1
    优先权日:2005-09-15
    标 题 :Chloroquine combination drugs and methods for their synthesis
    发明人:KOSAK KENNETH M
    权利人:KOSAK KENNETH M
    摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

    专利号:US-2006040879-A1
    优先权日:2004-08-21
    标 题:Chloroquine coupled nucleic acids and methods for their synthesis
    发明人:KOSAK KENNETH M
    权利人:KOSAK KENNETH M
    摘要:This invention discloses compositions and methods for preparing chloroquine-coupled nucleic acid compositions. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the nucleic acid needs to be released, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to a nucleic acid directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing nucleic acids for therapeutic or other medical uses. The invention also discloses nucleic acid carrier compositions that are coupled to targeting molecules for targeting the delivery of nucleic acids to their site of action.

    专利号:US-2005153913-A1
    优先权日:2001-04-10
    标 题 :Nucleic acid carrier compositions and methods for their synthesis
    发明人:KOSAK KENNETH M
    摘要:This invention discloses compositions and methods for preparing pharmaceutical nucleic acid carriers. The compositions comprise a carrier substance coupled to a nucleic acid intercalator whereby the intercalator is coupled by intercalation to the nucleic acid. The compositions can also include a biocleavable linkage for carrying and releasing nucleic acids for therapeutic or other medical uses. The invention also discloses nucleic acid carrier compositions that are coupled to targeting molecules for targeting the delivery of nucleic acids to their site of action.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ueberschaar N, Meyer F, Dahse HM, Hertweck C. Bipiperidine conjugates as soluble sugar surrogates in DNA-intercalating antiproliferative polyketides. Chem Commun (Camb). 2016 Apr 7;52(27):4894-7. doi: 10.1039/c6cc00890a. Epub 2016 Mar 14. doi: 10.1021/ja4080024. Epub 2013 Nov 6. doi: 10.1002/rcm.6663.
    5: Xu Z, Jakobi K, Welzel K, Hertweck C. Biosynthesis of the antitumor agent chartreusin involves the oxidative rearrangement of an anthracyclic polyketide. Chem Biol. 2005 May;12(5):579-88. Review.
    11: Asai G, Yamamoto N, Toi M, Shin E, Nishiyama K, Sekine T, Nomura Y, Takashima S, Kimura M, Tominaga T. Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer. Cancer Chemother Pharmacol. 2002 Jun;49(6):468-72. Epub 2002 Apr 9. Review. Japanese.

    合成参考文献


    参考文献:10.1385/1-59259-057-8:149
    摘要:Shen LL. DNA-unwinding test using eukaryotic DNA topoisomerase I. Methods Mol Biol. 2001;95():149–60. doi: 10.1385/1-59259-057-8:149.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知